RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today provided an additional update on the compassionate use program with its investigational drug, opaganib (Yeliva®, ABC294640)1, in patients with confirmed SARS-CoV-2 infection (COVID-19) in Israel.
April 17, 2020
· 10 min read